JP2016516043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516043A5 JP2016516043A5 JP2016502444A JP2016502444A JP2016516043A5 JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5 JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- optionally
- compound according
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 7
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004419 alkynylene group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(*)(*)N(*)*c1ccccc1 Chemical compound *C(*)(*)N(*)*c1ccccc1 0.000 description 16
- WHELBNUVILHIHT-UHFFFAOYSA-N Cc(cc1)ccc1-c1ncc[o]1 Chemical compound Cc(cc1)ccc1-c1ncc[o]1 WHELBNUVILHIHT-UHFFFAOYSA-N 0.000 description 8
- DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc2ccccc2[s]1 Chemical compound Cc1nc2ccccc2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 3
- FKWHHXZNCQKLJG-UHFFFAOYSA-N CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O FKWHHXZNCQKLJG-UHFFFAOYSA-N 0.000 description 2
- ALHUXMDEZNLFTA-UHFFFAOYSA-N Cc1nc2ccccc2nc1 Chemical compound Cc1nc2ccccc2nc1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 2
- WGTUMQXQVLOHQE-UHFFFAOYSA-N CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O Chemical compound CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O WGTUMQXQVLOHQE-UHFFFAOYSA-N 0.000 description 1
- VGZHYZHNXNVWHH-UHFFFAOYSA-N CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 Chemical compound CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 VGZHYZHNXNVWHH-UHFFFAOYSA-N 0.000 description 1
- QEYUNVXPSOCBAG-UHFFFAOYSA-N CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 Chemical compound CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 QEYUNVXPSOCBAG-UHFFFAOYSA-N 0.000 description 1
- QMBLXRHXCGJOGU-UHFFFAOYSA-N CCc1ccc(CC(O)=O)cc1 Chemical compound CCc1ccc(CC(O)=O)cc1 QMBLXRHXCGJOGU-UHFFFAOYSA-N 0.000 description 1
- BHIQFQYCZIJUIG-UHFFFAOYSA-N CCc1ccc(CC(OC)=O)cc1 Chemical compound CCc1ccc(CC(OC)=O)cc1 BHIQFQYCZIJUIG-UHFFFAOYSA-N 0.000 description 1
- OLPWVSINLQYDIY-UHFFFAOYSA-N CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O OLPWVSINLQYDIY-UHFFFAOYSA-N 0.000 description 1
- YMXQNJHJWAVADX-UHFFFAOYSA-N CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 Chemical compound CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 YMXQNJHJWAVADX-UHFFFAOYSA-N 0.000 description 1
- JBOVVZBMLVRDAP-UHFFFAOYSA-N CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 Chemical compound CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 JBOVVZBMLVRDAP-UHFFFAOYSA-N 0.000 description 1
- LJVIXOQEJPEWJW-UHFFFAOYSA-N CNCc(cc1)cnc1NCCC(O)=O Chemical compound CNCc(cc1)cnc1NCCC(O)=O LJVIXOQEJPEWJW-UHFFFAOYSA-N 0.000 description 1
- YCESUPDCBCISGX-UHFFFAOYSA-N CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC Chemical compound CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC YCESUPDCBCISGX-UHFFFAOYSA-N 0.000 description 1
- VYMYSBRLXXKRPA-UHFFFAOYSA-N CNCc1ccc(N(C)CC(O)=O)nc1 Chemical compound CNCc1ccc(N(C)CC(O)=O)nc1 VYMYSBRLXXKRPA-UHFFFAOYSA-N 0.000 description 1
- RPLYIPWVKQPFFL-UHFFFAOYSA-N CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 Chemical compound CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 RPLYIPWVKQPFFL-UHFFFAOYSA-N 0.000 description 1
- UDOMVKIVDINFMC-UHFFFAOYSA-N COC(c1ccc(CSC)cc1)=O Chemical compound COC(c1ccc(CSC)cc1)=O UDOMVKIVDINFMC-UHFFFAOYSA-N 0.000 description 1
- GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
- KCTZYAAHUYSVON-UHFFFAOYSA-N OC(c1ccc(CS)cc1)=O Chemical compound OC(c1ccc(CS)cc1)=O KCTZYAAHUYSVON-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781168P | 2013-03-14 | 2013-03-14 | |
| US61/781,168 | 2013-03-14 | ||
| PCT/US2014/027449 WO2014152536A2 (en) | 2013-03-14 | 2014-03-14 | Inhibitors of leukotriene a4 hydrolase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516043A JP2016516043A (ja) | 2016-06-02 |
| JP2016516043A5 true JP2016516043A5 (OSRAM) | 2017-04-13 |
| JP6562898B2 JP6562898B2 (ja) | 2019-08-21 |
Family
ID=51581719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502444A Active JP6562898B2 (ja) | 2013-03-14 | 2014-03-14 | ロイコトリエンａ４加水分解酵素の阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9822106B2 (OSRAM) |
| EP (1) | EP2968265A4 (OSRAM) |
| JP (1) | JP6562898B2 (OSRAM) |
| KR (1) | KR20150131211A (OSRAM) |
| AU (2) | AU2014239585B2 (OSRAM) |
| BR (1) | BR112015022227A2 (OSRAM) |
| CA (1) | CA2906086A1 (OSRAM) |
| MX (1) | MX2015011676A (OSRAM) |
| RU (1) | RU2690489C2 (OSRAM) |
| WO (1) | WO2014152536A2 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| MY199220A (en) | 2015-11-19 | 2023-10-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| JP6911031B2 (ja) | 2015-12-22 | 2021-07-28 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 免疫調節剤としての複素環化合物 |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MY197280A (en) | 2016-06-20 | 2023-06-09 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EP3551611A1 (en) | 2016-12-09 | 2019-10-16 | Celtaxsys Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| PT3558990T (pt) | 2016-12-22 | 2022-11-21 | Incyte Corp | Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA47099A (fr) | 2016-12-22 | 2021-05-12 | Incyte Corp | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| WO2019036024A1 (en) | 2017-08-17 | 2019-02-21 | Bristol-Myers Squibb Company | 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
| US10925851B2 (en) | 2018-03-15 | 2021-02-23 | Regents Of The University Of Minnesota | Use of Tosedostat and related compounds as analgesics |
| HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| ES3014615T3 (en) | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| PH12022550754A1 (en) | 2019-09-30 | 2023-08-23 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
| EP4196478A1 (en) | 2020-08-14 | 2023-06-21 | Novartis AG | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815872A (OSRAM) * | 1967-11-22 | 1969-05-27 | ||
| US4582833A (en) | 1984-04-16 | 1986-04-15 | American Cyanamid Company | 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines |
| US4576943A (en) | 1984-10-09 | 1986-03-18 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines |
| US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
| US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
| AU3577995A (en) * | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| WO1997029774A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| US5925654A (en) * | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| WO1999048873A1 (en) * | 1998-03-25 | 1999-09-30 | Bristol-Myers Squibb Company | Imidazolone anorectic agents: i. acyclic derivatives |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| CZ20013767A3 (cs) * | 1999-05-17 | 2002-04-17 | Novo Nordisk A/S | Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6924313B1 (en) * | 1999-09-23 | 2005-08-02 | Pfizer Inc. | Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| WO2001056990A2 (en) * | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| DE60114518T2 (de) | 2000-07-06 | 2006-08-10 | Fuji Photo Film Co. Ltd., Minamiashigara | Flüssigkristallzusammensetzung, die Flüssigkristallmoleküle und Ausrichtungsmittel enthält |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| US7012075B2 (en) | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| AU2002336532C1 (en) | 2001-09-14 | 2008-10-16 | Amgen, Inc | Linked biaryl compounds |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2003093297A2 (en) * | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| UA80437C2 (en) * | 2002-09-19 | 2007-09-25 | Lilly Co Eli | Diaryl ethers as opioid receptor antagonist |
| WO2005027886A2 (en) | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| AU2003290527A1 (en) | 2002-10-17 | 2004-05-04 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction |
| AU2003300360A1 (en) * | 2002-12-20 | 2004-07-22 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| CA2521000A1 (en) | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or therapeutic agent for neuropathic pain |
| WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| KR20060054408A (ko) * | 2003-07-28 | 2006-05-22 | 얀센 파마슈티카 엔.브이. | 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도 |
| EP1669348A4 (en) * | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| ATE437880T1 (de) | 2004-02-04 | 2009-08-15 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
| WO2006033795A2 (en) | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| KR20080003385A (ko) * | 2005-03-31 | 2008-01-07 | 얀센 파마슈티카 엔.브이. | 페닐 및 피리딜 ｌｔａ４ｈ 조절제 |
| EP1879863A1 (en) * | 2005-05-03 | 2008-01-23 | Pfizer, Inc. | Amide resorcinol compounds |
| CA2610671A1 (en) * | 2005-05-31 | 2006-12-07 | Astrazeneca Ab | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| JP5133889B2 (ja) | 2005-09-21 | 2013-01-30 | デコード ジェネティクス イーエイチエフ | 炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤 |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| EP1878730A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| WO2008016131A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| CN101528709B (zh) | 2006-10-19 | 2012-02-01 | 弗·哈夫曼-拉罗切有限公司 | 对痕量胺相关受体有亲和性的氨基甲基-2-咪唑类 |
| US7893257B2 (en) | 2006-12-14 | 2011-02-22 | Janssen Pharmaceutica Nv | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| CN101687844B (zh) | 2007-07-02 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr2受体拮抗剂的咪唑衍生物 |
| AU2008285795A1 (en) * | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands |
| AU2008334444B2 (en) | 2007-12-12 | 2011-12-15 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors |
| FR2928070A1 (fr) * | 2008-02-27 | 2009-09-04 | Sumitomo Chemical Co | Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes. |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| KR101228378B1 (ko) * | 2008-04-11 | 2013-01-31 | 얀센 파마슈티카 엔.브이. | 류코트리엔 α4 하이드롤레이즈의 조정제로서의 티아졸로피리딘-2-일옥시-페닐 및 티아졸로피라진-2-일옥시-페닐 아민 |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| CN102030700B (zh) | 2009-09-30 | 2016-06-01 | 中国医学科学院药物研究所 | 苯甲酰胺基羧酸类化合物及其制法和药物用途 |
| AU2010328419A1 (en) | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| JP2013047189A (ja) * | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
| TR201802550T4 (tr) * | 2011-03-14 | 2018-03-21 | Boehringer Ingelheim Int | Lökotrien üretiminin benzodioksan inhibitörleri. |
| SG193424A1 (en) * | 2011-03-15 | 2013-10-30 | Rib X Pharmaceuticals Inc | Antimicrobial agents |
| ES2557450T3 (es) * | 2011-05-23 | 2016-01-26 | Janssen Pharmaceutica, N.V. | Derivados de ácido picolinamido-propanoico útiles como antagonistas de los receptores de glucagón |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
-
2014
- 2014-03-14 CA CA2906086A patent/CA2906086A1/en not_active Abandoned
- 2014-03-14 KR KR1020157028770A patent/KR20150131211A/ko not_active Ceased
- 2014-03-14 RU RU2015137977A patent/RU2690489C2/ru not_active IP Right Cessation
- 2014-03-14 MX MX2015011676A patent/MX2015011676A/es unknown
- 2014-03-14 WO PCT/US2014/027449 patent/WO2014152536A2/en not_active Ceased
- 2014-03-14 JP JP2016502444A patent/JP6562898B2/ja active Active
- 2014-03-14 BR BR112015022227A patent/BR112015022227A2/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014239585A patent/AU2014239585B2/en not_active Ceased
- 2014-03-14 EP EP14769620.7A patent/EP2968265A4/en not_active Withdrawn
-
2015
- 2015-09-10 US US14/849,829 patent/US9822106B2/en active Active
-
2017
- 2017-11-02 US US15/801,494 patent/US20180118735A1/en not_active Abandoned
-
2019
- 2019-07-02 AU AU2019204753A patent/AU2019204753A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516043A5 (OSRAM) | ||
| JP2016513696A5 (OSRAM) | ||
| JP2016513681A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2015522650A5 (OSRAM) | ||
| JP2015520769A5 (OSRAM) | ||
| JP2016506961A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| JP2019501125A5 (OSRAM) | ||
| JP2011513305A5 (OSRAM) | ||
| JP2015537020A5 (OSRAM) | ||
| JP2014506907A5 (OSRAM) | ||
| JP2016526576A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2014506599A5 (OSRAM) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2013512903A5 (OSRAM) | ||
| JP2015500887A5 (OSRAM) | ||
| JP2017508782A5 (OSRAM) | ||
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2017526677A5 (OSRAM) | ||
| JP2014508804A5 (OSRAM) | ||
| JP2018527295A5 (OSRAM) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 |